Every DEF 14A that Silexion Therapeutics Corp (SLXN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SLXN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLXN filings page.
Silexion Therapeutics Corp (SLXN) is seeking shareholder approval to add 500,000,000 authorized ordinary shares, increasing the authorized total from 15,900,000 to 515,900,000, subject to proportionate adjustment if the reverse-split proposal is also approved. Shareholders are also being asked to authorize a reverse split at a ratio from 1-for-15 to 1-for-25. The Board will select a ratio for shareholder approval and, if approved, may implement the split after the meeting. Both proposals are scheduled for a vote on October 19, 2026.
The company says the additional authorized shares would support Nasdaq shareholders’ equity compliance and clinical-program funding. Shareholders’ equity was approximately $3.177 million as of September 30, 2026, compared with $44,000 as of June 30, 2026; Nasdaq’s minimum is $2.5 million. The company received a deficiency notice after its closing bid price was below $1.00 for 30 consecutive business days, and a Nasdaq hearings panel is considering its compliance plan. Silexion says the authorization increase itself would not issue shares, but future issuances could dilute existing holders. 14,473,292 ordinary shares were outstanding as of September 30, 2026.
Silexion Therapeutics Corp (SLXN) is asking shareholders at a September 9, 2026 extraordinary general meeting to approve two capital-structure changes aimed at preserving its Nasdaq Capital Market listing and funding development of its RNAi oncology programs.
Proposal 1 would increase authorized share capital by 175,000,000 ordinary shares, from 15,900,000 to 190,900,000 shares (par value $0.135), an 1,100% increase in authorization. As of August 24, 2026, 5,755,872 ordinary shares were outstanding and significant portions of the remaining authorization are reserved for warrants, equity plans, an at-the-market program, and a promissory note to Moringa Sponsor, L.P.; an internal table shows the current plan usage would exceed the 15.9 million authorized shares. Management links this increase to maintaining compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of shareholders’ equity, and to providing capacity for future financings and business development.
Proposal 2 would authorize a reverse share split of all issued and authorized ordinary shares at a ratio between 1-for-7 and 1-for-15, with the exact ratio set by the board before the meeting. The split is intended to support compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Rule 5550(a)(2); Silexion has already completed 1-for-9, 1-for-15, and 1-for-10 reverse splits since 2024. The board states that percentage ownership and voting rights per holder will remain the same, except for rounding of fractional shares, and that authorized share count and par value will be adjusted proportionally.
Silexion Therapeutics Corp is calling an extraordinary general meeting on July 13, 2026 to seek shareholder approval for two capital-related proposals tied to its Nasdaq listing and clinical funding needs.
The first proposal asks shareholders to approve the exercisability of 399,020 new Series C and D warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share that were issued in a May 18, 2026 warrant inducement financing which raised about $1.0 million and helped restore compliance with Nasdaq’s $2.5 million shareholders’ equity requirement.
The second proposal would increase authorized share capital by 10,000,000 ordinary shares to a total of 15,900,000 shares, giving Silexion more capacity to issue equity for financings, operations and potential business development while maintaining its Nasdaq Capital Market listing as it begins Phase 2/3 trials for SIL‑204.
Silexion Therapeutics Corp is asking shareholders to approve three major capital-structure changes at an extraordinary general meeting on April 28, 2026. The board wants to increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, citing a lack of unissued shares and the need to maintain at least $2.5 million of shareholders’ equity required by Nasdaq.
A second proposal would amend the 2024 Equity Incentive Plan’s evergreen provision so that, each January 1, the pool reserved under all equity plans equals 10% of issued and outstanding shares on a fully diluted basis, up from a 5% of outstanding-shares formula. The third proposal authorizes a reverse share split of all ordinary shares, at a ratio between 1‑for‑4 and 1‑for‑10, to help keep the Nasdaq bid price above $1.00 and avoid potential delisting, without changing each holder’s percentage ownership aside from minor rounding of fractional shares.
Silexion Therapeutics Corp is asking shareholders at a March 16, 2026 extraordinary general meeting to approve two key changes. The first would increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, mainly to support financing, business development and compliance with Nasdaq’s $2.5 million shareholders’ equity requirement. The second would amend the 2024 Equity Incentive Plan so the annual “evergreen” refresh can raise the total equity incentive pool up to 10% of issued and outstanding ordinary shares on a fully diluted basis. As of February 23, 2026, Silexion had 3,330,785 ordinary shares outstanding. The board unanimously recommends voting in favor of both proposals.